16 November2026: OBI Pharma signs collaboration and license agreement with Novartis
OBI Pharma entered into a collaboration and license agreement with Novartis Pharma AG to develop next-generation ADC using OBI’s proprietary ADC platform technologies and novel payloads. Novartis receives exclusive worldwide rights to OBI’s related patents and know-how for selected, undisclosed payload classes, with an option to expand the agreement to additional payload classes
The collaboration is at the platform development stage, with no specific ADC candidate, clinical trial, NCT number or clinical efficacy data disclosed. OBI and Novartis will evaluate novel linker approaches in combination with Novartis’s proprietary payloads to generate next-generation ADC candidates
The collaboration aims to develop differentiated ADCs incorporating novel payload classes and optimized linker technologies, potentially expanding therapeutic approaches for cancer patients. however, the specific tumour indications, molecular targets and intended patient populations have not yet been disclosed
The collaboration focuses on next-generation ADCusing OBI’s proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI® and GlycOBI DUO®.OBI will also evaluate novel linker approaches with Novartis payloads to optimize ADC development. specific antibody targets, payload classes and linker chemistries remain undisclosed
The agreement includes a $30 million upfront payment, with potential development, regulatory and commercial milestone payments bringing the total deal value to more than $2 billion, in addition to tiered royalties on future net sales. collaboration strengthens OBI’s position as an ADC technology partner and validates the commercial potential of its proprietary platforms